The results of the present analysis, estimating over 41,000 LYG thanks to the addition of trastuzumab to CT in HER2+ early breast cancer women in Spain, shows that the drug substantially improves the prognosis of patients with HER2+ eBC. Here, ERBB2 is linked to breast carcinoma.